<DOC>
	<DOCNO>NCT00997373</DOCNO>
	<brief_summary>Some case endometrial cancer dependent estrogen growth . Letrozole block estrogen production body . The purpose study determine investigator predict patient might benefit Letrozole treatment study many different form estrogen receptor molecule exist within cancer tissue . To participate study , patient must 40 year age old biopsy-proven endometrial carcinoma , either well differentiate moderately differentiated form . Also , eligible participate study , patient need healthy enough hysterectomy . If patient le age 60 , need blood test ( FSH ) confirm go menopause .</brief_summary>
	<brief_title>Letrozole Treatment Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>FIGO grade 1 2 endometrioid adenocarcinoma endometrium Post menopausal status must demonstrate Signed informed consent FIGO grade 3 endometrioid adenocarcinoma nonendometrioid cancer endometrium Younger 40 postmenopausal status establish Pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Endometrial Carcinoma</keyword>
	<keyword>Aromatase Inhibitor</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Femara</keyword>
</DOC>